Wells Fargo & Company Lineage Cell Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 71,367 shares of LCTX stock, worth $45,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,367

Previous 67,441 5.82%

Holding current value

$45,674

Previous $67,000 4.48%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.8 - $1.12 $3,140 - $4,397	3,926 Added 5.82%	71,367 $64,000
Q2 2024 Aug 13, 2024	BUY	$0.89 - $1.47 $6,287 - $10,385	7,065 Added 11.7%	67,441 $67,000
Q1 2024 May 10, 2024	SELL	$0.86 - $1.48 $497 - $856	-579 Reduced 0.95%	60,376 $89,000
Q4 2023 Feb 09, 2024	BUY	$0.91 - $1.35 $7,992 - $11,857	8,783 Added 16.83%	60,955 $66,000
Q3 2023 Nov 13, 2023	SELL	$1.16 - $1.53 $32,116 - $42,361	-27,687 Reduced 34.67%	52,172 $61,000
Q2 2023 Aug 15, 2023	BUY	$1.26 - $1.53 $66,733 - $81,033	52,963 Added 196.92%	79,859 $112,000
Q1 2023 May 12, 2023	SELL	$1.2 - $1.53 $64 - $82	-54 Reduced 0.2%	26,896 $40,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $1.5 $21,871 - $32,164	21,443 Added 389.38%	26,950 $31,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $3,387 - $5,306	-2,998 Reduced 35.25%	5,507 $6,000
Q2 2022 Aug 12, 2022	SELL	$1.12 - $1.61 $217,845 - $313,153	-194,505 Reduced 95.81%	8,505 $13,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $389,415 - $798,140	-321,831 Reduced 61.32%	203,010 $312,000
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $330,469 - $481,336	-179,603 Reduced 25.5%	524,841 $1.29 Million
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $1.57 Million - $1.98 Million	693,901 Added 6581.63%	704,444 $1.78 Million
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $1,974 - $2,730	910 Added 9.45%	10,543 $30,000
Q1 2021 May 13, 2021	SELL	$1.77 - $3.1 $215,389 - $377,235	-121,689 Reduced 92.66%	9,633 $22,000
Q4 2020 Feb 09, 2021	BUY	$0.95 - $1.83 $1,981 - $3,817	2,086 Added 1.61%	131,322 $231,000
Q3 2020 Nov 05, 2020	SELL	$0.75 - $1.09 $19,398 - $28,192	-25,865 Reduced 16.68%	129,236 $121,000
Q2 2020 Aug 13, 2020	SELL	$0.71 - $1.18 $103,141 - $171,418	-145,270 Reduced 48.36%	155,101 $135,000
Q1 2020 May 14, 2020	BUY	$0.6 - $1.58 $180,222 - $474,586	300,371 New	300,371 $249,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $109M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Lineage Cell Therapeutics, Inc. Transaction History